Brief Psychiatric Rating Scale (BPRS)
18-item clinician-administered scale assessing psychiatric symptoms in patients with major mental illness, particularly schizophrenia. Each item 1–7. Total 18–126. Widely used in clinical trials and acute settings.
Score interpretation
BPRS 18–30 — below the score linked to CGI 'mildly ill'
→ Outpatient management; optimise antipsychotic; psychotherapy (CBT for psychosis); close follow-up; consider community mental health team
BPRS 31–40 — about CGI 'mildly ill'
→ Outpatient management; optimise antipsychotic; psychotherapy (CBT for psychosis); close follow-up; consider community mental health team
BPRS 41–52 — about CGI 'moderately ill'
→ Consider antipsychotic dose review or medication change; regular psychiatric review; psychosocial interventions; assess need for crisis resolution or home treatment team
BPRS ≥ 53 — about CGI 'markedly ill' or worse
→ Urgent psychiatric assessment; inpatient admission consideration; assess risk (suicide, homicide, vulnerability); clozapine if treatment-resistant; MDT care planning
Interpretation bands for the BPRS. Apply clinical judgement and local guidance.
References
- Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799–812.
- Leucht S, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366–371.
Related
Curated clinical cross-links plus same-class fallbacks.
- Risperidone (Paediatric) · Atypical Antipsychotic — Autism Spectrum Disorder / Schizophrenia / Tic Disorders
- Clozapine · Atypical antipsychotic (treatment-resistant schizophrenia)
- Sodium Valproate (Psychiatric use) · Mood stabiliser / Antiepileptic
- Lamotrigine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Depression
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Lorazepam (Psychiatric/Acute Use) · Benzodiazepine — Short-acting
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.